An interventional study of BeautiBond Xtreme pretreatment with BeautiLink SA cementation and HC Primer pretreatment with BeautiLink SA cementation in Bonding of Veneers After Different Treatment, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2025-06-18.
Sponsored by Cairo University · Not applicable, Interventional, and Treatment
This randomized controlled trial evaluates the clinical performance of laminate veneers fabricated from HC hard blocks pretreated with BeautiBond Xtreme versus HC Primer, using BeautiLink SA cement. The study focuses on marginal adaptation, retention, discoloration, and recurrent caries over 18 months.
This clinical trial compares two bonding protocols for hybrid ceramic laminate veneers. The veneers are fabricated from HC hard blocks and bonded using BeautiLink SA resin cement. One group receives BeautiBond Xtreme pretreatment, while the other receives HC Primer. The study assesses marginal adaptation, retention, recurrent caries, and discoloration over 18 months to determine the superior clinical bonding protocol for these restorations.
Cairo University is the lead sponsor of 4,780 studies on the registry; 1,427 are open to participants now.
Of its 36 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:dult patients ≥ 21 years requiring laminate veneers in the esthetic zone, vital or endodontically treated teeth, sufficient enamel, willing and able to consent and comply.
-
Exclusion Criteria: Periodontal disease, bruxism, poor hygiene, pregnancy, systemic illness, allergies, insufficient enamel, ongoing trials, orthodontic treatment.
-
atients in this group will receive laminate veneers fabricated from HC hard blocks. The inner surface of the veneers will be pretreated with BeautiBond Xtreme, and the veneers will be bonded using BeautiLink SA self-adhesive resin cement. This group is used to assess the clinical performance of BeautiBond Xtreme pretreatment over an 18-month follow-up.
Device: BeautiBond Xtreme pretreatment with BeautiLink SA cementation
atients in this group will receive laminate veneers fabricated from HC hard blocks. The inner surface of the veneers will be pretreated with HC Primer, and the veneers will be bonded using BeautiLink SA self-adhesive resin cement. This group serves as a comparator to evaluate differences in clinical outcomes relative to the BeautiBond Xtreme group.
Procedure: HC Primer pretreatment with BeautiLink SA cementation
Laminate veneers fabricated from HC hard blocks were pretreated on the internal surface with BeautiBond Xtreme, then bonded to tooth structure using BeautiLink SA self-adhesive resin cement. The tooth surfaces were also treated with BeautiBond Xtreme. Veneers were digitally designed and milled, then cemented following a standardized clinical protocol.
Laminate veneers fabricated from HC hard blocks were pretreated on the internal surface with HC Primer, then bonded to tooth structure using BeautiLink SA self-adhesive resin cement. The tooth surfaces were treated with BeautiBond Xtreme. Veneers were digitally designed and milled, then cemented following the same clinical protocol used in the experimental grou
Primary Outcome: Marginal Adaptation
(Modified USPHS)
Time frame: Measured at 6, 12, 18 months.
Plan to share: Undecided — this is a university-sponsored clinical study with a small sample size and limited scope. No plan to share individual participant data (IPD) has been established due to privacy considerations and the nature of the trial. However, summary-level results may be published in peer-reviewed journals and conferences.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cairo University